Figure 3From: Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agentsGeparQuattro study: cardiac events in women with HER2-positive and -negative breast cancer. CHF, congestive heart failure; CTC, crackle transmission coefficient; LVEF, left ventricular ejection fraction.Back to article page